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Introduction
The heart is a highly vascular organ, and prolonged
interruption of myocardial blood flow initiates cardiac
myocyte death.1 Reparative strategies consider har-
vesting potent cells followed by their direct injection
into ischemic myocardium to achieve myogenesis2,3 and
angiogenesis.4 However, these strategies have been
limited by the sources and fate of donor cells.5,6
We describe here the identification of primitive cells
from rat heart cardiac myocyte progenitors (CMPs),
expressing stem cell surface marker and myogenic tran-
scriptional factors with the potential of cardiomyogenic
differentiation. After transplantation, the cells could
survive and proliferate within the ischemic heart.
Progeny of implanted cells migrated toward the in-
farcted scar and reconstituted it with regenerated car-
diomyocytes incorporating into host myocardium. Our
findings suggest that CMPs isolated from adult heart
could potentially serve as an autologous cell source
for cell therapy to achieve myocardial regeneration.
Methods
Isolation and purification of CMPs
This study was approved by Taipei Veterans General
Hospital’s Animal Committee, and the Principles of
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Laboratory Animal Care (NIH publication no. 86-23,
revised 1985) were followed. Hearts from 10 male
Sprague-Dawley rats (∼250 g each, from National
Laboratory Animal Center, Taipei) were placed in cold,
sterile calcium-free DMEM (Gibco). The atria and
upper portion of the ventricles were removed by dis-
section, and the remaining tissue was cut into pieces
(∼2 mm cubes). After treatment with trypsin (0.25%;
Gibco) and collagenase type II (0.1%; Gibco), tissue
chunks were placed in calcium-free DMEM contain-
ing 1% bovine serum albumin (BSA; Sigma) and
100 µM CaCl2, teased apart with forceps and further
disrupted by repeated up-and-down pipetting. Tissue
clumps were then allowed to settle repeatedly at 1g;
centrifugation of the combined supernatants at 25g
for 5 minutes yielded mature myocytes and non-myocyte
cells that were suspended in calcium-free DMEM-1%
BSA containing 500µM CaCl2 and layered over 5 mL
of calcium-free DMEM containing 6% BSA.
Centrifugation at 25g for 5 minutes separated a clear
upper layer (1% BSA), a darker 6% BSA layer and the
myocyte pellets.
The 6% BSA fraction from this gradient centrifuga-
tion, which contained cardiac primitive cells and endo-
thelial cells, was placed in DMEM containing 10% fetal
bovine serum (FBS; Sigma) on collagen-coated plates
(10 µg/cm2). After overnight incubation, most of the
endothelial cells attached to the plates, while non-
adherent cardiac primitive cells were collected and
placed in DMEM and Ham’s F12 (ratio 1:1) contain-
ing 10% FBS on regular plates. After 7–10 days, most
cells became attached, and these were called cardiac
myocyte progenitors (CMPs). They were continuously
grown at subconfluent densities with serial passages.
All media contained 100 µ/mL penicillin, 100 µg/mL
streptomycin, and 2.5 µg/mL amphotericin B.
Cell immunocytochemistry
CMPs at passages 2 and 7 were grown on glass cover-
slips and permeabilized with ice acetone for 10 minutes.
Immunocytochemical staining was performed with
antibodies for stem cell surface marker c-kit (Santa
Cruz Biotechnology) for myogenic transcriptional
factor GATA-4 (Santa Cruz Biotechnology) and for
heart-specific proteins troponin-I (cTn-I) (Serotec),
α-sarcomeric actinin (α-SA) (Sigma) and connexin-43
(Sigma). Fluorescein isothiocyanate (FITC)-conjugated
secondary antibody (Chemicon) and propidium iodide
(PI) for nuclear counterstaining were used.
Flow cytometry
The isolated and expanded CMPs were characterized
at passage 2 by flow cytometric analysis of stem cell
surface marker c-kit. The cells were harvested from the
culture dishes and then stained for 30 minutes on ice
with anti c-kit antibody (Santa Cruz Biotechnology)
and then FITC-conjugated secondary antibody
(Chemicon). The cell mixture was then washed twice
with washing buffer (PBS/1% of FBS/0.1% of NaN3)
and fixed in 1% paraformaldehyde in PBS. Cells were
analyzed using a fluorescence-activated cell sorter
(FACS) (Vantage SE; Becton Dickinson) using 
a 525 nm bandpass filter for green FITC fluorescence.
Reverse transcriptase–polymerase chain
reaction
Total RNA was extracted from CMPs and adult rat
heart by Trizol Reagent (Life Technologies). Reverse
transcriptase–polymerase chain reaction (PCR) of myo-
genic specific genes, including GATA-4, MEF-2C
and Myf-5 was performed. cDNA was synthesized
from total RNA (1 µg) using M-MuLV reverse tran-
scriptase, and PCR was performed using cDNA as the
template in a 30µL reaction mixture containing a spe-
cific primer pair of each cDNA according to the pub-
lished sequences (Table 1). The reaction mixture was
incubated initially at 95°C for 1 minute, followed by
25–35 cycles of denaturation at 95°C for 30 seconds,
annealing at 53–60°C for 1.5 minutes and 72°C for 
1 minute with an additional 7-minute incubation at
72°C after completing the last cycle (number of PCRs
optimized in each case to ensure that the intensity of
each product fell within the linear phase of amplifica-
tion). DNA product was separated by electrophoresis
in 1% agarose gel, stained and photographed under
UV light. β-actin was used as the internal control.
Cell labeling and preparation for
implantation
Sterile CellTracker Orange stock solution (Molecular
Probes) was added to the serum-free medium at a final
concentration of 10 µM on the day of implantation.7
The dye was allowed to remain in the culture dishes
for 30 minutes and then replaced with complete
medium, followed by incubating CMPs (passage 2)
for another 30 minutes. CMPs were then rinsed 6 times
in PBS to remove the dye outside the cells. CMPs
were collected (approximately 1×106 cells for 1 implan-
tation) and resuspended in minimal volume of serum-
free medium and stored on ice (less than 1 hour) until
implantation into the myocardium.
Surgical procedure
Ten male Sprague-Dawley rats (∼250 g each) were
subjected to ligation of the left anterior descending
coronary artery to produce myocardial infarction, as
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previously described.8 In brief, rats were anesthetized
with enflurane (Ethrane), intubated, and ventilated
with 1.5–2% of enflurane in oxygen. Left thoracotomy
was performed at the fourth intercostal space, the
pericardium was gently ruptured, and the heart was
exteriorized. The left anterior descending coronary
artery was ligated 2–3 mm from its origin at about the
level of the tip of the left auricular appendage with 
a permanent 7-0 polypropylene suture. The heart was
returned to the chest, the rib space and overlying
muscles were closed, and the lungs were re-inflated
by positive expiratory pressure. After recovery from
anesthesia and extubation, the rats were returned to
their cages. They were given water and standard rat
chow and housed in a climate-controlled environment
with a 12-hour light/12-hour dark cycle.
Two weeks after myocardial infarction, rats were
anesthetized and underwent left thoracotomy again,
during which the heart was carefully dissected free of
adhesions to visualize the extent of left ventricular
infarction. Then, 1 × 106 CMPs (passage 2) were
injected at 3 or 4 points in the region bordering the
infarct. Thereafter, the thoracotomy was closed, and
the rats were allowed to recover.
Two weeks later, the rats were sacrificed. They
were lightly anesthetized with enflurane and placed in
a supine position. Median sternotomy was performed
to expose the heart and great vessels. The RA was cut
open, the ascending aorta was cannulated using a 22-G
angiocatheter, and the distal aorta was ligated. High-
potassium solution 50 mL (5 mL KCL in 500 mL
normal saline) was administered at 100 cmH2O via
the catheter to arrest the heart in diastole. Later, 50 mL
of 4% paraformaldehyde was infused through the
coronary system to fix the heart at physiologic pressure.
The hearts were excised and placed into ice-cold
saline to allow the heart to remain in diastole and to
remove the remaining blood. After removal of the
atria and great vessels, the right ventricular free wall
was excised. The left ventricle was transversely sec-
tioned into 4 segments from apex to base and fixed in
4% paraformaldehyde in phosphate-buffered saline
(pH 7.4), paraffin-embedded, and sectioned.
Intraperitoneal 5-bromo-2-deoxyuridine (BrdU)
(Sigma) was given (50 mg/kg) 12 hours before the
sacrifice of rats to evaluate the proliferation of
implanted CMPs.
Tissue immunohistochemistry
Immunohistochemical staining with antibodies against
BrdU and the cardiac specific markers cTn-I, α-SA and
connexin-43 were performed on the cryosections of
individual blocks. FITC-conjugated second antibody
was used. The proliferation rate of implanted CMPs
was evaluated by examination of 5 randomly selected
fields of sections from a series of blocks. Proliferative
CMPs were recognized as cells co-localized with Cell-
Tracker Orange in the cytoplasm and BrdU in the
nucleus.
Results
Characteristics of CMPs in vitro
We separated small non-myocyte cells from myocytes
by gradient centrifugation first. Small non-myocyte
cells included cardiac primitive cells, fibroblasts,
endothelial cells and hematopoietic cells. We further
separated these cells by selective adhesion. Most of the
fibroblasts and endothelial cells adhered quickly to the
collagen-coated plates and were discarded. The non-
adherent cells were transferred to medium with DMEM
and Ham’s F12 (ratio 1:1) containing 10% FBS on
regular plates. CMPs then preferably attached and were
separated from other cells by this selective culture
media. Using these methods, we successfully isolated
CMPs from 10 rats (∼500 cells/rat). They were con-
tinuously grown at subconfluent densities with serial
passages at intervals of around 7–10 days. After passage
7 (∼6 × 106 CMPs/rat), they appeared to have reached
growth arrest and senescence with morphologic
changes from small nuclear-dominant cells to flat
cytoplasm-rich cells (Figure 1A vs. 1D and 1E).
By immunocytochemistry and flow cytometry
(data not shown), over 50% of CMPs expressed stem
cell surface marker, c-kit (Figure 1A), at passage 2.
These cells also demonstrated differentiation through
myogenic lineage by activating genes of myogenic
transcriptional factors including GATA-4, MEF-2C
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Table 1. PCR primers
GATA-4
Sense, 5-AGACATCGCACTGACTGAGAA-3
Antisense, 5-GACGGGTCACTATCTGTGCAA-3
MEF-2C
Sense, 5-CCGATGCAGACGATTCAGTAG-3
Antisense, 5-GTGTCACACCAGGAGACATAC-3
Myf-5
Sense, 5-GAGCCAAGAGTAGCAGCCTTCG-3
Antisense, 5-GTTCTTTCGGGACCAGACAGGG-3
β-actin
Sense, 5-CAGCTTCTCTTTAATGTCACG-3
Antisense, 5-GGGTCAGAAGGACTCCTACGT-3
and Myf-5 (Figure 1C). Moreover, GATA-4 could be
detected on almost all CMPs (Figure 1B). No cardiac
specific proteins were demonstrated at this point (data
not shown). However, these cells expressed cardiac
specific markers, cTn-I (Figure 1D), α-SA (Figure
1E) and connexin-43 (Figure 1F) at passage 7 when
they were no longer proliferating rapidly.
CMPs sustained proliferation ability after
transplantation
We injected 1 × 106 CellTracker-labeled CMPs into the
peri-infarcted area of the rat hearts. At another 2 weeks
after injection, we treated the rats with BrdU and
used BrdU immunoreactivity as a marker of cells
undergoing division. By counting the number of
CellTracker-labeled cells and the number of such cells
co-localized with BrdU immunostain, we estimated
that 13.63 ± 5.97% of CMPs expressed proliferative
ability 2 weeks after implantation (Figures 2A–C).
CMPs migrated along infarcted scar
We observed clusters of CMPs oriented in the same
direction as the native cardiomyocytes in the border
zone and in the myocardial scar (Figure 2D). These
findings demonstrated that CMPs could integrate with
host myocardium and migrate specifically toward
infarcted scar.
CMPs expressed markers of cardiomyocytes after
transplantation
To address whether implanted CMPs contributed to
myocardial regeneration, we examined their pheno-
type expression after transplantation. Immunostaining
showed that labeling of CellTracker co-localized with
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Figure 1. Characterization of CMPs in vitro. Cells were processed at: (A, B, C) passage 2;
and (D, E, G) passage 7. (F) Cytofluorimetric profile of c-kit marker. Immunocytochemical
staining with FITC-labeled secondary antibodies (green) for: (A) c-kit; (B) GATA-4; (D) cTn-I;
(E) α-SA; (G) connexin-43 (arrowheads indicate connexin-43 staining on cell membrane). 
A and B are overlays of double images with nuclei stained with propidium iodide (red). RT-
PCR analysis of GATA-4, MEF-2C and Myf-5 expression of CMPs in C. Scale bars = 50 µm 
in A, B, D and E and 20 µm in F. Rat ventricle = positive control; β-actin = loading internal
control.
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Figure 2. (Continued)
cardiac specific cTn-I (Figures 2E–G) and α-SA
(Figures 2H–J). Labeled CMPs also expressed connein-
43 (Figures 2K–M) at contact points with each other
and native cardiac myocytes. Together, these results
established that implanted CMPs expressed cardiomy-
ocytic phenotype and that they connect with each
other by gap junctions.
Discussion
CMPs can be used as donor cells for myocardial
regeneration
In this study, we used adult CMPs as cell therapy for
the ischemic rat heart because we wanted to correlate
with the situation of using autologous cells in aging
humans. Autologous cardiac cells might be more
effective than other cells in the setting of cell therapy
for myocardial regeneration.9 However, isolated adult
cardiomyocytes have no ability to divide as they have
been withdrawn from cell cycle.10 Recent studies sug-
gest that the heart may not be a post-mitotic organ,
and that myocyte renewal occurs throughout life in
the normal or diseased myocardium.11,12 In patients
with aortic stenosis, investigators found intense new
myocardium formation from cardiac stem cells.13
They further isolated these cells by antibody-based
techniques to evaluate the feasibility of using these
cells to repair the acute ischemic heart.8
Different from their results, the CMPs isolated
here expressed a lower percentage (50% vs. 90%) of c-
kit with an extremely high percentage (∼100% vs. 7%)
of myogenic transcriptional factor, GATA-4. After serial
passages, they expressed cardiac specific proteins
including cTnI, α-SA and connexin-43. Compared
with the results from Anversa and Nadal-Ginard’s
study,9 which showed that isolated cells are clono-
genic and multipotent, our results demonstrated that
CMPs are a heterogeneous population as to its stage
of differentiation, and that most of them are already
committed and restricted to the myogenic lineage.
After implantation, CMPs still preserve their myogenic
phenotypes, including contractile proteins (cTnI and
α-SA) and gap junction protein (connexin-43).
Furthermore they appear to integrate with host cardiac
myofibers, which is essential for implanted cells to
improve cardiac function. Further studies to compare
their efficacy with other sources for myocardial regen-
eration would be highly desirable.
CMPs can proliferate in vivo
Previous experiments have shown that it is possible to
generate new myocardium by cell therapy, but the
amount of new myocardium is severely limited by cell
death.6,14 An alternative strategy to obtain an adequate
quantity of graft tissue would be to introduce a smaller
number of cells initially, which would, however, be
capable of proliferation in vivo. CMPs isolated by our
method demonstrated proliferating ability (about 14%)
2 weeks after being implanted into the ischemic heart.
This characteristic may represent a superior feature
compared to other potential donor cell sources to re-
place a substantial fraction of the myocardium lost due
to infarction.
CMPs have many theoretical advantages as donor
cells for myocardial regeneration. They are already
lineage-committed to cardiomyocytes, thus may not be
affected in their differentiation by an adverse microenvi-
ronment, such as that of scar tissue. They can be autolo-
gous, so there is no need for immunosuppression. They
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Figure 2. Proliferation, migration and cardiomyocyte phenotype expression of implanted CMPs. Sections were from hearts 2 weeks
after implantation and stained for: (A) BrdU; (E) cTn-I; (H) α-SA; and (K) connexin-43 with FITC-labeled secondary antibodies (green).
(B, D, F, I, L) CellTracker-labeled CMPs (orange). (C, G, J, M) Overlays of double images. Arrowheads in C and E–M indicate cells co-localized
with immunostain markers and CellTracker. Arrowheads in D show the border zone of scar in infarcted hearts. Arrow in E indicates the
host cardiomyocyte. Scale bars = 10 µm in A–C, 500 µm in D, 50 µm in E–G and K–M, and 100 µm in H–J.
MLK
can be vastly multiplied in number in vitro, and are
capable of in vivo replication, thus addressing the issues
of cell loss after implantation as well as the quantitative
requirement of cell therapy to replace a great loss of
myocardial tissue as often encountered clinically. Har-
vesting and expanding CMPs from a biopsy obtained
from the healthy portion of the patient’s heart and im-
planting them back into the infarcted area, for example,
could be a strategy worthy of further exploration.
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